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Little is known about the molecular mechanisms
that control adrenomedullin (AM) production in hu-
man cancers. We demonstrate here that the ex-
pression of AM mRNA in a variety of human tumor
cell lines is highly induced in a time-dependent
manner by reduced oxygen tension (1% O2) or ex-
posure to hypoxia mimetics such as desferrioxam-
ine mesylate (DFX) or CoCl2. This AM expression
seems to be under hypoxia-inducible factor-1
(HIF-1) transcriptional regulation, since HIF-1a and
HIF-1b knockout mouse cell lines had an ablated
or greatly reduced hypoxia AM mRNA induction.
Similarly, inhibition or enhancement of HIF-1 activ-
ity in human tumor cells showed an analogous
modulation of AM mRNA. Under hypoxic condi-
tions, immunohistochemical analysis of tumor cell
lines revealed elevated levels of AM and HIF-1a as
compared with normoxia, and we also found an
increase of immunoreactive AM in the conditioned
medium of tumor cells analyzed by RIA. AM mRNA
stabilization was shown to be partially responsible
for the hypoxic up-regulated expression of AM. In
addition, we have identified several putative hyp-
oxia response elements (HREs) in the human AM
gene, and reporter studies with selected HREs
were capable of enhancing luciferase expression
after exposure to DFX. Furthermore, transient co-
expression of HIF-1a resulted in an augmented
transactivation of the reporter gene after DFX
treatment. Given that most solid human tumors
have focal hypoxic areas and that AM functions as
a mitogen, angiogenic factor, and apoptosis-sur-
vival factor, our findings implicate the HIF-1/AM
link as a possible promotion mechanism of carci-
nogenesis. (Molecular Endocrinology 14:848–862,
2000)
INTRODUCTION
Adrenomedullin (AM) is a recently discovered hypo-
tensive peptide isolated from a human pheochromo-
cytoma (1). The cDNAs for human, rat, mouse, pig, and
cow AM have been cloned and the genomic organi-
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zation profile for human and mouse identified (2, 3).
This peptide has been shown to mediate a multifunc-
tional response in cell culture and animal systems that
includes regulation of cardiovascular tone, bronchodi-
lation, modulation of central brain function, natriuretic
and diuretic action, antimicrobial activity, inhibition of
hormone release, growth regulation, apoptosis sur-
vival, and induction of angiogenesis (see review in
Refs. 4–6).
Several prior reports have demonstrated AM and its
corresponding receptor (AM-R) to be ubiquitously ex-
pressed during embryogenesis and carcinogenesis.
Early in both mouse and rat fetal development AM/
AM-R are first detected in the heart, and then they
appear progressively in other anatomical sites during
organogenesis (7, 8). Maternal decidual cells and em-
bryonic cells (fetal cytotrophoblast giant cells) of the
ectoplacental cone, a site that mimics the invasion
process of carcinogenesis, also show abundant ex-
pression of AM/AM-R (8, 9). After its initial identifica-
tion in a human pheochromocytoma, further studies
have demonstrated increased AM expression in tumor
tissue of ganglioneuroblastoma, neuroblastoma, and
adrenocortical carcinomas (10, 11). In addition, AM
plasma levels are elevated in patients with gastroin-
testinal or lung cancer (12). Our group has shown that
AM and AM-R are expressed in human tumor cell lines
of the lung, breast, colon, ovary, prostate, brain, car-
tilage, and blood (13). In several of these lines, AM
functioned as an autocrine proliferation factor whose
effect could be inhibited by a neutralizing monoclonal
antibody (MoAb-G6) causing growth cessation in vitro
(13). Recently, it has been shown that hypoxic condi-
tions or exposure to CoCl2 (a transition metal that
mimics hypoxia) induces an increase in AM mRNA
expression and protein production in a human colo-
rectal carcinoma cell line, DLD-1 (14).
Focal areas of low oxygen tension (#2.0% O2) are
inherent to the biological processes of embryogene-
sis, wound repair, and carcinogenesis (15–17). A state
of diminished free oxygen availability results when re-
gional growth demands exceed the oxygen supply of
the capillary bed (15). Under such conditions, an ox-
ygen-sensing mechanism activates a transcription
factor known as hypoxia-inducible factor-1 (HIF-1),
which in turn up-regulates a series of genes that sup-
port the cell to compensate for the potentially lethal
microenvironment (18). HIF-1 is a heterodimer com-
posed of HIF-1a and HIF-1b/ARNT (aryl hydrocarbon
receptor nuclear translocator) subunits, both repre-
senting members of the PAS (Per, ARNT, Sim) basic-
helix-loop-helix family (18). Transcription/translation
products of HIF-1a and HIF-1b are constitutively ex-
pressed; however, the HIF-1a protein contains an
oxygen-dependent degradation domain that is rapidly
cleaved by the ubiquitin-proteasome pathway under
normoxic conditions, thus enabling the modulation of
HIF-1 activity in an oxygen-dependent manner (19).
Genes transactivated by HIF-1 include aldolase A,
enolase 1, erythropoietin (Epo), glucose transporter 1,
heme oxygenase 1, inducible nitric oxide synthase,
lactate dehydrogenase A, phosphofructokinase L,
phosphoglycerate kinase 1, transferrin (Tf), vascular
endothelial growth factor (VEGF), and endothelin-1
(ET-1) (18, 20). Low oxygen tension is known to play a
critical role in embryonic development, causes the
emergence of drug/radiation-resistant tumor cells, en-
hances mutagenesis of neoplastic lesions, and ele-
vates metastatic potential of the tumor (15, 21–24).
The way AM gene expression is regulated in human
tumors is not yet known, but a decrease in oxygen
tension could be a major cause for the induction of this
molecule. In our present study we actually demon-
strate the ability of hypoxia and hypoxia mimetics to
up-regulate the AM message and protein expression
in a variety of human tumor cell lines. We also made
use of both molecular and biochemical characteriza-
tion approaches to support that this induction is me-
diated by transactivation of the AM promoter by HIF-1
transcription factor as well as posttranscriptional
mRNA stabilization.
RESULTS
AM mRNA Induction in Human Tumor Cell Lines
under Hypoxic Treatments
Northern analysis for AM mRNA expression in a
variety of human tumor cell lines (cancers of the
lung, breast, colon, ovary, prostate, bone, and
blood) demonstrated a consistent increase in mes-
sage induced by exposure to 1% O2, desferrioxam-
ine (DFX), or CoCl2. All 17 cell lines evaluated in this
manner showed inducible AM expression, and Fig. 1
illustrates a representative example of the observed
responses to our test conditions (6 h exposure to
100 mM CoCl2, 6 h exposure to 260 mM DFX or 12 h
exposure to 1% O2). Interestingly, although there is
variability of expression in the basal AM mRNA lev-
els between cell lines [the two pulmonary cancer cell
lines NCI-H1264 (adenocarcinoma) and NCI-H157
(squamous cell carcinoma) being the opposing ex-
tremes], all tumor cell lines show increases in AM
message expression on exposure to our hypoxic
test conditions, with calculated test/basal ratios
ranging from 1.3- to 25-fold.
We have used MCF7 (breast adenocarcinoma) as
our standard human cancer cell line for all time course
studies with exposures to CoCl2, DFX, or 1% O2.
Figure 2, A–C, demonstrates the induction of AM mes-
sage at different time increments over a 24–48 h ex-
posure series. Note that although CoCl2 exposure
causes AM mRNA levels to reach a maximum at 8 h,
both DFX and 1% O2 induced an AM message zenith
at 12 h, indicating a potential mechanistic difference
between test reagents. Induced maximum levels of
AM message are maintained with all the hypoxia treat-
ments tested at 24 h of exposure, and even elevated
levels are still observed at 48 h of exposure to 1% O2.
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Of the three treatments, exposure to 1% O2 is the one
that shows a steeper induction of AM mRNA over time,
and also more dramatic increases between the basal
and the maximum induction are observed (.25-fold
increase between maximum induction and baseline
levels).
We have also performed a parallel analysis for
HIF-1a mRNA in MCF7 cells throughout the hypoxic
studies. HIF-1a transcript levels remained constant or
showed a slight decline over time in the CoCl2 and 1%
O2 time course studies (Fig. 2, A and C). This obser-
vation is in accordance with other reports indicating
that HIF-1a is mainly regulated not at the transcrip-
tional level but by protein stabilization in hypoxia,
whereas the protein is rapidly degraded by the
ubiquitin-proteasome pathway during normoxic con-
ditions (19, 25).
Under Hypoxic Conditions, AM Is Also Induced at
the Protein Level
To address whether the induction of AM mRNA was
accompanied by an increase in the production of AM
protein, the presence and cellular localization of AM
and HIF-1a in tumor cell lines at normoxic or hypoxic
conditions were studied using double immunofluores-
cence followed by confocal microscopy. A typical im-
age is shown in Fig. 3, in which prostate carcinoma DU
145 cells are immunostained for both AM (green fluo-
rescence) and HIF-1a (red fluorescence). At normoxic
conditions (Fig. 3, A and B), both AM and HIF-1a are
moderately expressed in the cytoplasm and nucleus of
the cells. After 12 h exposure to 260 mM DFX, the cells
showed a marked increase of AM staining in the cy-
toplasm and nucleus (Fig. 3C); in agreement with our
previous results (26) HIF-1a immunoreactivity is pri-
marily elevated in the nucleus of the cells (Fig. 3D).
Similar patterns of staining were obtained with H157,
MCF7, and SNUC-1 cell lines (data not shown).
Since we and other investigators have reported a
rapid secretion of the bioactive processed AM peptide
by human tumor cells and endothelial cells (13, 27), we
also examined the presence of AM in the conditioned
medium of MCF7 under hypoxic conditions. As is
shown in Fig. 4, a significant increase in immunoreac-
tive AM (IR-AM) was observed for MCF7 cells treated
Fig. 1. Up-Regulation of AM mRNA in Several Human Tumor Cell Lines under Hypoxic Treatments
Northern blot analysis for AM of cells exposed either to hypoxia mimetics (100 mM CoCl2, 260 mM DFX) for 6 h, or to a
hypoxic atmosphere (1% O2, 5% CO2, 94% N2) for 12 h, as compared with untreated cells. Cell lines shown here were
selected from a total of 17 cell lines tested and also chosen as representatives of the main human tumor types: carcinomas
of the lung (N417d, H1264, H157), breast (H2380), colon (SNUC-1), ovary (K-OV-3), prostate (DU 145), or chondrosarcoma
(HTB-94). Fifteen micrograms of total RNA were loaded per lane, and ethidium bromide staining of 28 S rRNA was used to
check for equal loading and RNA integrity.
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with 1% O2 at various times as compared with the
cells maintained in normoxic conditions. Increasing
values of accumulated IR-AM in the conditioned me-
dia of this cell line were also observed for the CoCl2 or
DFX treatments (data not shown).
The Hypoxic Induction of AM mRNA Is
Dependent on HIF-1
To determine whether the hypoxic up-regulation of AM
mRNA was driven by HIF-1, we used cell lines derived
from HIF-1a or HIF-1b knockout mice to evaluate AM
induction capabilities as compared with those of their
wild-type counterparts under hypoxic treatments. Fig-
ure 5A illustrates an experiment designed to compare
AM mRNA levels in these cell lines when subjected to
6 h treatment of CoCl2 or DFX. It is shown that HIF-1a
null (2/2) mouse fibroblast cells failed to induce AM
mRNA expression in these conditions, while the wild-
type HIF-1a (1/1) fibroblasts showed an inducible
response. Similarly, normal HIF-1b (1/1) mouse em-
bryonic stem (ES) cells demonstrated an inducible re-
sponse, whereas HIF-1b null (2/2) ES cells showed a
32% and a 60% reduced induction when compared
with the wild-type control, depending on the test re-
agent examined.
In addition, when HIF-1a 1/1 and HIF-1a 2/2 cell
lines were exposed to a hypoxia (1% O2) time course
study (Fig. 5B), the hypoxic induction of AM mRNA
was not detectable on the cells with the null mutation,
although it was present in the wild-type cells. We also
analyzed the levels of HIF-1a message expression in
this experiment. Note that HIF-1a mRNA remained
constant through the hypoxia treatment; however,
HIF-1a transcripts in HIF-1a 2/2 cells present a
higher molecular size than in the corresponding wild-
type cells, since the null mutation was obtained by
replacement of the helix-loop-helix domain of HIF-1a
with a neomycin resistance cassette (28).
Furthermore, artificial manipulation of HIF-1 activity
with appropriate biochemical reagents was also used
to elucidate the role of this transcription factor in AM
message regulation under hypoxia. In this sense, the
nitric oxide donor sodium nitroprusside (SNP) as well
as genistein (a tyrosine kinase inhibitor), are known to
inhibit HIF-1 activity by blocking the synthesis of HIF-1
subunits and/or interfering with HIF-1 DNA binding
activity in hypoxia (29, 30). MCF7 cells were cultured
for 12 h in normoxic or hypoxic conditions, with or
without the appropriate biochemical reagents, and AM
mRNA expression was analyzed comparing the
treated vs. the nontreated cells (control). As is shown
in Fig. 6, addition of 100 mM SNP completely inhibited
the induced expression of AM mRNA after 12 h of
hypoxia (1% O2) treatment, while genistein at 100 mM
was a less potent suppressor of the AM mRNA induc-
tion mediated by low oxygen tension. Thus, the inhib-
ited activity of HIF-1 with SNP and genistein is corre-
lated with a suppressive effect on the AM mRNA
hypoxic induction. Conversely, it has been reported
that the CO scavenger hemoglobin (Hb) enhances
HIF-1 activity by increasing HIF-1 DNA binding (31).
Treatment of MCF7 cells with 50 mM Hb was shown to
further increase AM mRNA expression under hypoxic
conditions by approximately 1.7-fold (Fig. 6).
Stabilization of AM Transcripts under Hypoxia
Hypoxia-induced up-regulation of gene expression
can be mediated both by de novo synthesis of mRNA
and by stabilization of the normally labile mRNAs un-
der hypoxic conditions. To test whether the latter pos-
sibility was involved in the induced response of AM to
Fig. 2. Time Course Analysis of AM Expression
Northern blot analysis of MCF7 cells cultured under 100
mM CoCl2 (A), 260 mM DFX (B), or 1% O2 (C) for the indicated
times. Fifteen micrograms of total RNA were loaded per lane
and hybridized subsequently with human AM and human
HIF-1a cDNA probes. Equal loading was monitored by
ethidium bromide staining of 28 S rRNA for each blot.
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hypoxia, we examined the half-life of AM transcripts
under normoxic and hypoxic conditions in the pres-
ence of actinomycin D, a compound known to inhibit
RNA synthesis. MCF7 cells were maintained under
hypoxic (1% O2) conditions for 12 h to sufficiently
induce the expression of AM transcripts, and AM
mRNA level at this point was considered the standard
to which the rest of the samples were compared. After
the initial hypoxic induction, actinomycin D was added
at 4 mg/ml, and the cells were further maintained at
normoxic or hypoxic (1%O2) conditions from 1 to 4 h.
As shown in Fig. 7, AM mRNA clearly decayed more
rapidly under normoxic than under hypoxic conditions,
thus indicating a stabilization process in hypoxia.
Densitometry analysis of the degradation of AM
mRNA under normoxia and hypoxia in this experiment
was performed, and the pooled data resulted in a
calculated half-life of the AM mRNA of 1.7 h under
normoxia and of 2.5 h under hypoxia. Our data thus
indicate that the hypoxia-induced expression of AM
transcripts is at least partially dependent upon stabi-
lization of AM mRNA.
Identification of Putative Hypoxia-Response
Element (HRE) Sites in the Human AM Gene
Since it is known that HIF-1 mediated gene transacti-
vation involves its binding to distinct nucleic acid mo-
tifs, namely HREs, we used GCG computer software
from Genetics Computer Group (Madison, WI) to an-
alyze the human and mouse AM genes (GenBank ac-
cession nos. D43639 and D78349, respectively) for
appropriate HRE sequences. In this analysis we fol-
lowed the HRE consensus motif proposed by Wenger
and Gassmann (18, 32): (T,G,C) (A,G) CGTG (C,G,A)
(G,T,C) (G,T,C) (C,T,G), which has been constructed
from the nucleotide sequence of HIF-1 binding sites of
13 oxygen-dependent genes, and allowed for no more
than a single base mismatch outside the CGTG core
sequence. We have analyzed not only the 59-promoter
region but also the 39-flanking region, introns/exons,
Fig. 3. Double Immunostaining for AM and HIF-1a on DU 145 Cells Analyzed by Confocal Microscopy
Cells were grown on glass slides, left under normoxic conditions (A and B), or treated with 260 mM DFX for 12 h (C and D), and
then immunostained for AM and HIF-1a. Equal microscope settings and exposures were maintained on images from normoxic/
DFX-treated cells, to compare expression under both conditions. Both AM (A and C) and HIF-1a (B and D) become markedly
overexpressed after 12 h of DFX treatment. Bar 5 5 mm.
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and looked for consensus motifs in both sense and
antisense strands, since these genomic areas have
been previously shown to have functional HRE sites in
other HIF-1-inducible genes (18, 20, 33). With these
premises, eight putative HRE sites at the 59- and six
sites at the 39-untranslated flanking sequences of the
human AM gene were found, together with putative
HRE sequences in the first intron and in exon 3 and
exon 4 (see Fig. 8). Similar analysis of the mouse AM
gene identified three putative HRE sites in the anti-
sense strand of the 59-promoter region (positions:
21143, [AACTCACGgA]; 298, [CAAGCACGCt]; and
262, [tGACCACGCC]), and another three on the
sense orientation: one in intron 1 (position 533,
[CGCGTGCTGa]), one in intron 2 (position 727, [Gc-
CGTGCTTT]), and finally one at exon 4 (position: 1960,
[GACGTGAaTG]).
Luciferase Reporter Assays for the Human AM
Promoter Region under Hypoxia
To determine whether these HRE sites were actually
involved in the regulation of AM mRNA expression,
luciferase reporter studies were performed for differ-
ent regions of the 59-flanking region of the human AM
gene. MCF7 cells were transiently transfected with the
empty parental plasmid (pGL2basic) or with con-
structs comprising one, two, four, or eight putative
HREs of the AM promoter (see Fig. 9A). A cotrans-
fected b-galactosidase expression vector served as
internal control for transfection efficiency and extract
preparation. After the transfection, cells were left un-
der normoxic conditions or exposed to 260 mM DFX for
24 h, and luciferase activity was determined. No sig-
nificant increase for the luciferase activity in the DFX-
treated cells/normoxic cells was obtained when trans-
fections were performed with constructs containing
the one or two putative HREs closest to the TATA box
(Fig. 9A). However, when cells were transfected with
constructs containing four or eight putative HREs sites
at the 59-end of the TATA box, a significant (P , 0.01)
1.5- and 1.7-fold increase in luciferase activity was
observed when comparing DFX-treated vs. normoxic
cells.
To test whether we could potentiate the increase in
luciferase activity for the DFX treated/normoxic cells,
we performed transient expression experiments using
the HIF-1a expression vector pCMVb-HA-HIF-1a (34).
This expression vector was cotransfected into MCF7
cells together with the empty parental vector or plas-
mid constructs containing four or eight HREs from the
AM promoter (pGL2basic, pGL2b-4, or pGL2b-8), and
the normalization b-galactosidase plasmid. A repre-
Fig. 4. RIA of IR-AM in the Conditioned Media of MCF7 Cells Cultured under Normoxia or 1% O2 Atmosphere
After 12 h treatment, levels of AM detected in the conditioned medium of cells in both conditions are similar; however, at 24 h,
values of accumulated IR-AM in cultured media of 1% O2 treated cells were significantly higher than those from normoxic cells
(**, P 5 0.004). Values are the mean 6 SEM.
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sentative experiment is shown in Fig. 9B, in which the
transient overexpression of HIF-1a augmented the lu-
ciferase reporter activity after DFX treatment up to
2.9-fold when four HREs were present, and up to
4.8-fold with eight HREs as compared with the values
of transfected cells in normoxic conditions; no signif-
icant increase was observed when the HIF-1a expres-
sion vector was cotransfected with the pGL2basic
empty vector.
DISCUSSION
Oxygen availability is known to play a key role in the
growth-regulatory process underlying carcinogenesis
(15). Seminal work by Semenza and collaborators (35,
36) demonstrated the general involvement of HIF-1 in
the transcriptional response to hypoxia. Since then,
several established growth modulation factors, includ-
ing Epo, VEGF, Tf, ET-1, and insulin-like growth factor
binding protein 1 (IGFBP-1), have been shown to be
under HIF-1 transcriptional control (18, 20, 33). Based
on previous reports showing that AM functions as an
autocrine growth factor for certain human tumor cell
lines (13), we began a comprehensive study to deter-
mine whether hypoxia could influence the expression
of AM via HIF-1 in human tumor cell lines as an in vitro
approach for similar conditions occurring in solid hu-
man cancers.
Our initial analysis by Northern blot in a variety of
human tumor cell lines clearly demonstrates that hyp-
oxia increases mRNA levels in these cells as com-
pared with the untreated controls. Interestingly, there
is a considerable variation in the basal levels of AM
mRNA observed in normoxic conditions. High levels of
basal AM mRNA may arise from the constitutive ex-
pression of HIF-1a protein in certain cells, a condition
that has been previously reported for primary cultures
of human pulmonary arterial smooth muscle cells (37).
Fig. 5. Northern Blot Analysis on HIF-1a and HIF-1b Knockout Mouse Cell Lines
Fifteen micrograms of total RNA were loaded per lane, and equal loading and integrity of RNA were monitored by ethidium bromide
staining of 28 S rRNA. A, AM mRNA induction is suppressed in fibroblast HIF-1a 2/2 cells or reduced in ES HIF-1b 2/2 cells treated
with CoCl2 or DFX for 6 h as compared with their wild-type counterparts. B, Hypoxia (1% O2) time course study on HIF-1a wild-type
(1/1) and HIF-1a null cells (2/2) probed for mouse AM and HIF-1a. Note that HIF-1a null cells fail to induce AM mRNA expression.
Fig. 6. Expression of AM mRNA in MCF7 Cells Treated with
Reagents That Modulate HIF-1 Activity
Northern blot analysis was performed on MCF7 cells cul-
tured for 12 h in a normoxic or hypoxic (1% O2) fashion with
or without 50 mM Hb, 100 mM SNP, or 100 mM genistein. The
hypoxic induction of AM transcripts in hypoxia was further
augmented with Hb (a reagent that enhances HIF-1 activity),
whereas SNP and genistein (known to inhibit HIF-1 activity)
had a suppressive effect on that induction.
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In the time course experiments using MCF7 cells sub-
jected to an hypoxic environment, we also demon-
strate that the AM mRNA induction is paralleled by a
somewhat delayed increased secretion of AM peptide
from the cells to the conditioned media. Given our
prior finding that endogenous AM functions as an au-
tocrine growth factor for MCF7 (13), the demonstration
that hypoxia augments bioactive AM production and
secretion in these cells suggests that a similar sce-
nario may take place in tissue neoplasms. The pro-
duction and secretion of AM at the hypoxic areas
present in tumors (15) could establish an autocrine/
paracrine-mediated proliferation event leading to tu-
mor growth. In addition, since AM has angiogenic and
vasodilator capabilities (1, 6), the secreted AM could
induce neovascularization and facilitate nutritional
supplementation to the tumor cells. Finally, AM also
has been shown to protect cells from apoptosis (5),
and this feature could selectively rescue tumor cells
from programmed cell death and might even predis-
pose tumors to a more malignant phenotype (15).
The data obtained with the HIF-1a and HIF-1b
knockout mouse cell lines, together with those from
the HIF-1 biochemical modulation studies performed
on MCF7 cells, provide consistent evidence support-
ing the major involvement of HIF-1 in the transcrip-
tional activation of AM by hypoxia and suggest that
AM could be considered a new member of the growing
family of HIF-1-targeted genes. The absence of induc-
ible AM mRNA expression in HIF-1a null mouse fibro-
blast cell line under hypoxia seems to highlight the
critical importance of the HIF-1a subunit in the trans-
activation of AM mRNA. Recent studies with HIF-1a
knockout mice have shown this genetic deletion to be
an embryonic lethal event in the later stages of fetal
development (28, 38). In addition, tumors derived from
mouse ES cells with HIF-1a null genotype have re-
tarded growth, reduced VEGF expression, and less
angiogenesis than their wild-type counterparts (28).
Given that AM is also highly expressed during embry-
ogenesis (8), it would be interesting to evaluate
whether there are modifications in the AM distribution
patterns in early HIF-1a null embryos. HIF-2a, a hy-
poxia-inducible transcription factor sharing homology
with HIF-1a, has recently been shown to be essential
in embryonic vascularization and catecholamine pro-
duction (39); we cannot exclude a possible role of
HIF-2a in AM transactivation in endothelial and cat-
echolamines-producing cells of embryos as well as
catecholamines-producing tumors. In contrast to
HIF-1a knockout cell lines, ES HIF-1b null cells under
hypoxia showed a diminished AM mRNA induction as
compared with their wild-type counterparts, which
may reflect the ability of other basic helix-loop-helix
family members (e.g. ARNT 2 and ARNT 3) to com-
pensate for the loss of HIF-1b in the formation of a
functional heterodimer with HIF-1a, albeit at lower
efficiency (40, 41).
Prior studies have demonstrated the ability of re-
duced oxygen tension to mediate elevations in AM
message/protein expression in several animal and cell
systems. In this sense, hypoxia was shown to induce
AM gene expression and secretion in cultured human
umbilical vein endothelial cells (42); focal ischemic
regions of the rat brain show high AM mRNA expres-
sion (43), and patients with chronic obstructive pulmo-
nary disease involving tissue hypoxia have elevated
AM plasma levels (44). Nakayama and colleagues (14)
have demonstrated that hypoxia can elevate AM
mRNA and protein expression in a single human colo-
rectal carcinoma cell line, DLD-1; however, these in-
vestigators did not identify any HRE motifs in the 59-
upstream flanking region of the human AM gene and
suggested the possible involvement of AP-1 in the
hypoxia elevation they observed. Given that the AM
promoter has several AP-1 binding motifs and that
hypoxia can elevate c-fos, which in turn can activate
AP-1 expression (45, 46), their supposition had a log-
Fig. 7. Stabilization of AM Transcripts under Hypoxia
MCF7 cells were treated with 1% O2 for 12 h to induce the expression of AM mRNA. After addition of actinomycin D at 4 mg/ml,
cells were further maintained in normoxic or hypoxic conditions for the indicated times. Fifteen micrograms of total RNA were then
loaded in each lane for Northern blot analysis of AM transcripts. AM mRNA levels at each point were compared with levels
observed at 12 h hypoxia (previous to the addition of actinomycin D), and the half-life for AM transcripts under normoxic and
hypoxic conditions was estimated.
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ical basis and may in fact work in concert with our
observed HIF-1-driven AM expression. Recently, it
was also reported that the hypoxic expression of AM in
rodent cardiomyocytes is under HIF-1 control (47);
although Cormier-Regard and colleagues clearly dem-
onstrate the induction of AM mRNA under hypoxia, no
experimental data confirming a similar relationship for
AM peptide were shown.
In our luciferase reporter studies, MCF7 cells were
transfected with reporter plasmid constructs contain-
ing one, two, four, or eight of the putative HRE con-
sensus sequences that we identified in the human AM
promoter. Only when four or eight potential HREs were
present, a statistically significant fold increase in lucif-
erase expression was observed on exposure to DFX
over that of untreated controls. Although the luciferase
induction observed in our test conditions is modest, it
is within the range observed for the mouse AM gene
(47) and human Tf (48). For the human VEGF gene, it
has been reported that the increase in transcription
rate cannot account for all the observed increase in the
steady-state VEGF mRNA levels induced by hypoxia
Fig. 8. Schematic Drawing of Potential HRE Motifs in the Human AM Gene
Genomic structure was taken from GenBank accession no. D43639. Identification of putative HIF-1 binding sites is derived from
the HRE consensus sequence model of Wenger and Gassmann (18, 32), which represents the deca base region (T,G,C)(A,G)CGT-
G(C,G,A)(G,T,C)(G,T,C)(C,T,G), and allowing for only one base mismatch outside the CGTG core structure. HRE sites in the
schematic drawing are indicated by lowercase letters within circles. GCG analysis was performed in both sense and antisense
orientation, and nucleotide positioning of HRE sites was based on the AM transcriptional start site as 11. Accompanying chart
identifies numerical posititioning of HRE, single mismatched base, and 59- and 39-flanking sequences.
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Fig. 9. Evaluation of HRE Activity by Luciferase Reporter Assay
A, Hypoxia responsiveness of the human AM 59-flanking region. Schematic diagrams of the luciferase plasmids used in this
study, containing one, two, four, or eight putative HREs are shown on the left. The HRE sites are named in the same way as in
Fig. 8, and numbering refers to the region of the AM promoter inserted into the parental pGL2basic vector relative to the AM
transcription start site as 11. MCF7 cells were transiently transfected with one of the mentioned luciferase plasmids and a
pSV-b-galactosidase control vector. After normoxic or 260 mM DFX exposure for 24 h, luciferase acitivity was determined by
normalization to the corresponding b-galactosidase values. For each construct tested, fold increase of luciferase activities with
260 mM DFX vs. luciferase values in normoxia (arbitrarily defined as 1) are represented. Means 6 SEM of three to five independent
experiments are shown; **, P , 0.01, ***, P , 0.001. B, Transient expression of HIF-1a potentiates the enhanced luciferase activity
after exposure to DFX. MCF7 cells were transiently cotransfected with the HIF-1a expression vector (pCMVb-HA-HIF-1a) and the
plasmid constructs shown at the left of the figure. After normoxic or 24 h DFX (260 mM) treatment, the luciferase activity was
determined, corrected for transfection efficiency according to the b-galactosidase activity, and in each case normalized to the
luciferase value in normoxic conditions arbitrarily defined as 1.
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(49), and important posttranscriptional regulation
events mediated by mRNA stabilization do, in fact,
take place (50). A similar situation could also be de-
picted for the human AM gene, since not only tran-
scriptional activation but also, as we have shown, RNA
stabilization events contribute to the AM mRNA up-
regulation under hypoxic conditions. We cannot ex-
clude, however, the possibility of major functional HRE
sites at the 39-flanking region of the human AM gene,
a location that has been shown for HREs in the human
and mouse Epo gene (51, 52). Furthermore, when
MCF7 cells were cotransfected with a HIF-1a expres-
sion vector and plasmid constructs containing four or
eight HREs of the 59-flanking region of the human AM
gene, the increase in luciferase activity was remark-
ably potentiated as compared with the increase ob-
tained with the pGL2–4 or pGL2–8 plasmids alone.
This stimulated luciferase reporter activity with the
transient overexpression of HIF-1a has also been re-
ported for the human Tf, VEGF, and Epo genes (48,
53). These data further support that the transcriptional
activation of AM in hypoxic conditions is driven by
HIF-1 and not through other transcriptional factors
activated by hypoxia; additionally, they give stronger
evidence that at least some of the selected potential
HRE sites in the 59- flanking region of the human AM
gene are functional in the up-regulation of AM tran-
scription under hypoxia.
Based on our actinomycin D studies, we clearly
demonstrate AM mRNA stabilization mediated by hy-
poxic conditions. Recent studies on RNA degradation
mechanisms have identified hypoxia-inducible pro-
teins that bind to adenylate-uridylate (AU)-rich ele-
ments of the 39-untranslated region (39-UTR) of short
half-life RNA (i.e. VEGF, c-Myc, c-fos) and suppress
ribonuclease degradation (54, 55). One such stabiliz-
ing RNA-binding protein, HuR, has been shown to
interact with AUUUA or AUUUUA base sequences in
the 39-UTR of the VEGF mRNA and to extend its
half-life under hypoxic conditions (55). Interestingly,
the 39-UTR of both human and mouse AM mRNA have
AUUUA and AUUUUA sequences that could possibly
augment message survival during reduced oxygen
tension through a similar HuR or HuR-like interaction.
In addition, tumor cell lines that have a mutated von
Hippel-Lindau (VHL) tumor suppressor gene contain
constitutively stabilized VEGF mRNA and also have
constitutively expressed stabilizing RNA-binding pro-
teins (54). Considering these reports and the recent
discovery by Ratcliffe and co-workers that the VHL
gene product controls the degradation of HIF-1a pro-
tein (25), it will be interesting to determine the status of
the VHL suppressor gene in those human tumor cell
lines that have an elevated basal expression of AM
message under normoxic conditions (i.e. H157), to
determine whether this feature relates to an increased
half-life of AM mRNA mediated by constitutive expres-
sion of stabilizing RNA-binding proteins.
In conclusion, we have shown evidence in favor of
hypoxia as an inducer of AM mRNA and protein ex-
pression in human tumor cell lines. The data obtained
from HIF-1 knockout mouse cell lines, biochemical
modulation of HIF-1 activity, and transfection experi-
ments give solid proof for the involvement of HIF-1 in
the up-regulation of AM mRNA under hypoxic condi-
tions. In addition to HIF-1 transcriptional activation,
increased hypoxic mRNA stability also accounts for
AM induction based on our actinomycin D assays. Our
collective data, taken together with previous reports
that most solid human tumors have common hypoxic
regions (15) and that AM can function as a mitogen/
angiogenic factor/apoptotic survival factor (5, 6, 13),
implicate HIF-1/AM as members of a potential promo-
tion mechanism of carcinogenesis and identify a pos-
sible biological target for intervention strategies
against malignant disease.
MATERIALS AND METHODS
Cell Lines, Hypoxia Treatments, and Reagents
Cell lines used in this study were selected to represent an
array of the most widely distributed human cancer types. In
particular, we used representatives of carcinomas (CA) or
carcinoids of the lung [N417d (small cell CA), H1264 (ad-
enoCA), H157 (squamous cell CA), H720 (carcinoid)], breast
(H2380, MCF7, SK-BR-3, ZR-75), colon (H630, H716,
SNUC-1), ovary (OVCAR-3, SK-OV-3), prostate (DU 145, PC-
3-M), chondrosarcoma (HTB-94) or promyelocytic leukemia
(HL-60). All cell lines were obtained from the National Cancer
Institute-Navy Medical Oncology Branch or purchased
through the American Type Culture Collection (ATCC, Man-
assas, VA). All tumor cell lines were cultured in RPMI 1640 or
DMEM media supplemented with 10% heat inactivated FBS,
2 mM L-glutamine, 10 mM HEPES buffer, 100 U/ml penicillin,
and 100 mg/ml streptomycin (all tissue culture reagents pur-
chased from Life Technologies, Inc., Gaithersburg, MD). The
development, characterization, and maintenance of embry-
onic stem cell lines from HIF-1b knockout mice have been
previously described (56). The HIF-1a (2/2) fibroblast cell
line was generated from HIF-1a null mice (28) via SV-40
transformation of embryonic fibroblast cells; HIF-1a (2/2),
and (1/1) fibroblast cell lines were maintained with the same
media as specified for the human tumor cell lines.
Cells were cultured at 37 C in 20% O2, 5% CO2, 75% N2
for normoxic conditions, and new media were added 12 h
before the beginning of each hypoxia experiment. The hyp-
oxia induction was achieved either by hypoxia mimetics: 100
mM CoCl2, 260 mM DFX mesylate (both from Sigma, St. Louis,
MO), or by culturing cells in a hypoxia chamber at 37 C with
1% O2, 5% CO2, 94% N2 atmosphere. The hypoxia chamber
was fabricated from a Labconco seamless fiberglass vacuum
desiccator (Fisher Scientific, Pittsburgh, PA) fitted with two
stainless steel angle ball valves having serrated hose con-
nectors (Washington Valve & Fitting Co., Frederick, MD),
which allowed for chamber equilibration to hypoxic environ-
ment via venting with gas mixture (Roberts Oxygen Co.,
Gaithersburg, MD). The chamber was tested for leaks under
positive pressure using a bubble-forming agent (SNOOP,
Nupro Co., Willouhby, OH) and was shown to hold a 3 psi
charge for 48 h.
In the HIF-1 modulating studies, different agents were
added to the culture media, and then the cells were incubated
under normoxic conditions or in the hypoxia chamber for 12 h
at 37 C. SNP (a NO donor), and genistein (a tyrosine kinase
inhibitor), were used at 100 mM to inhibit HIF-1 activity (29,
30). Hemoglobin (Hb), which acts as a CO scavenger, was
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used at a final concentration of 50 mM to up-regulate HIF-1
activity (31); Hb was prepared by treatment with excess
reducing agent sodium dithionite (57). All reagents were pur-
chased from Sigma.
For the AM mRNA stabilization studies, cells were initially
exposed to 12 h hypoxia, after which actinomycin D was
added at a final concentration of 4 mg/ml (Sigma); cells were
subsequently maintained from 1 h to 4 h under normoxic or
hypoxic conditions.
Northern Blot Analysis
Immediately after treatment for the indicated times, cells
were washed once in PBS, and total RNA was extracted
using the guanidine isothiocyanate and cesium chloride
method (58). Fifteen micrograms of RNA were loaded per
lane, run in 1% agarose gels containing 2.2 M formaldehyde,
blotted by capillarity onto nitrocellulose membranes (Schlei-
cher & Schuell, Inc., Keene, NH), and baked for 2 h at 80 C.
Equal loading and integrity of RNA were monitored by
ethidium bromide staining of the 28 S subunit of rRNA.
The human AM cDNA probe used in this study was
generated as an RT-PCR product (831 bp) obtained using
oligonucleotide primers: 59-TACCTGGGTTCGCTCGCCTTC-
CTA-39 (sense, bp 184–207) and 59-CTCCGGGGGTCTCAG-
CATTCATTT-39 (antisense, bp 991-1014). The human HIF-1a
cDNA probe was also produced by RT-PCR (1308-bp prod-
uct) using oligonucleotide primers: 59-CGGCGCGAACGA-
CAAGAAAAAGAT-39 (sense, bp 43–66) and 59-TCGTT-
GGGTGAGGGGAGCATTACA-39 (antisense, bp 1327–1350).
Numbering of the nucleotide base positioning was taken from
the GenBank profile accession no. D14874 (human AM
mRNA) and U22431 (human HIF-1a mRNA). All RT-PCR
products were sequenced to validate base integrity of the
probes. The mouse AM cDNA 550-bp probe was a gift from
Dr. Sonia Jakowlew (59).
Probes were labeled with [a-32P]dCTP (3000 Ci/mmol;
NEN Life Science Products, Boston, MA) by random priming,
and unincorporated nucleotides were removed by Probe-
Quant G-50 Micro Columns (Amersham Pharmacia Biotech,
Piscataway, NJ). Hybridization was carried out overnight at
42 C in a hybridization buffer containing 40% formamide (58).
After stringency washes, blots were exposed to XAR film
(Eastman Kodak Co., Rochester, NY) at 280 C for varying
times. Densitometry of the autoradiograms was performed
using a ChemiImager 4000 (Alpha Innotech Corp., San Le-
andro, CA). The half-life of the endogenous AM mRNA was
calculated using Prism 3.0 software.
Confocal Immunofluorescence for AM and HIF-1a
Cells were grown on glass slides, treated with 260 mM DFX for
12 h, and fixed in Bouin’s fluid (Sigma) for 10 min at room
temperature. Slides were blocked with normal goat serum
(1:30 in PBS) for 30 min and then incubated overnight at 4 C
in a mixture of both antibodies: mgc3 antihuman HIF-1a
monoclonal antibody (60) at 1:500 dilution and rabbit antihu-
man AM 22–52 antibody (13) at 1:1,000 dilution. The second
layer consisted on a mixture of Rhodamine-antimouse and
Bodipy-antirabbit IgGs (Molecular Probes, Inc., Eugene, OR)
at a final concentration of 1:200 each. The cells were ob-
served with a Carl Zeiss Laser Scanning Microscope 510,
equipped with four lasers. Images from cells subjected to
DFX treatment and normoxic controls were taken with exactly
the same microscope settings and exposures, to compare
expression of AM and HIF-1a in both conditions.
RIA of Immunoreactive AM
Concentrations of AM in culture media of MCF7 cells under
hypoxia or mimetics treatment were measured by double
antibody RIA. Samples of culture media (1 ml) were mixed
with an equal volume of 0.1% alkali-treated casein in PBS,
pH 7.4, and applied to reverse-phase Sep-Pak C-18 car-
tridges (Waters Corp., Milford, MA). The proteins were eluted
with 3 ml of 80% isopropanol containing 0.125 N HCl and
lyophilized. Extracts were reconstituted in 0.4 ml of RIA buffer
(10 mM phosphate, 50 mM EDTA, 135 mM NaCl, 5 mM
NaHCO3, 0.05% Triton X-100, 0.1% Tween-20, 0.1% alkali-
treated casein, 20 mg/l phenol red, pH 7.4), and spun to
remove any solid matter. After a 24-h preincubation of 0.1 ml
of sample with 0.1 ml of antihuman AM antibody (Phoenix
Pharmaceuticals, Inc., Mountain View, CA) at 4 C, 0.1 ml of
125I-labeled AM (Phoenix Pharmaceuticals, Inc.) was added
(10,000 cpm) and the mixture was incubated at 4 C overnight.
Bound tracer was separated by polyethylenglycol-facilitated
precipitation with goat antirabbit IgG and normal rabbit se-
rum. After centrifugation, the supernatant was discarded, and
the radioactivity in the pellets was determined in a g-counter.
Data were statistically evaluated by a two-tailed Student’s t
test using Prism 3.0 software. Differences were regarded as
significant at a value of P , 0.05.
Reporter Plasmid Constructs
A PCR product of 118 bp (2118, 21) containing the putative
HRE site closest to the transcription start site in the 59-
flanking region of the AM gene (named HRE f in Fig. 8) was
generated using human genomic DNA as template and the
following oligonucleotide primers: sense, 59-GCTGAGGAAA-
GAAAGGGAAG-39 and antisense, 59-TGTCACCAAGAAAC-
CACTGA-39. Similarly, primers: sense, 59-AGCCCCAAAG-
GAAGCAATGC-39 and antisense, 59-TGTCACCAAGAAACC-
ACTGA-39 were used to generate a PCR product of 166 bp
(2166, 21) comprising the two potential HREs closest to the
transcription start site of the AM promoter (HREs named e
and f in Fig. 8). Each of the resulting 118-bp and 166-bp DNA
fragments were ligated into the pCR2.1 vector (Invitrogen,
Carlsbad, CA) to generate pCR2.1–118 and pCR2.1–166.
These plasmids were then digested with HindIII and XhoI, and
the resulting DNA fragments were cloned into the same sites
of a promoterless luciferase reporter pGL2basic (Promega
Corp., Madison, WI) to generate pGL2b-1 and pGL2b-2,
respectively.
The entire 59-flanking region of the human AM gene was
amplified by standard PCR from human genomic DNA using
primers: sense, 59-GAATTCAGGTCCGCTCAGGTGACTCCT-
TCC-39 and antisense, 59-GAGCTCGCTAGCCAGTGTCAC-
CAAGAAACC-39 (the antisense primer introduced a SacI site
[underlined] and an NheI site [bolded]). The resulting 1755 bp
(21751, 14) product was ligated into the pCR2.1 vector to
generate pCR2.1–1755. An NheI/NheI fragment from
pCR2.1–1755 was subcloned into the same site of
pGL2basic generating pGL2b-4 (which carries 4 putative
HREs from the 59-end of the AM promoter, namely c, d, e,
and f in Fig. 8). In the same way, a SacI/SacI fragment from
pCR2.1–1755 was also subcloned into the SacI site of
pGL2basic, generating pGL2b-8, which encompasses the 8
putative HREs in the 59-flanking region of the AM gene (HREs
a, b, c, d, e, f, q, and r in Fig. 8). The fidelity of all PCR-derived
sequences was verified by sequence analysis. All positions
are referred relative to the transcription start site of the AM
gene (11; see Fig. 8).
The HIF-1a expression vector (pCMVb-HA-HIF-1a) (34)
was generously provided by Dr. D. Livingstone (Dana Farber
Cancer Institute).
Transient Transfections and Luciferase Reporter Assay
Approximately 20 h before transfection 1.5 3 105 MCF7 cells
were seeded onto 60-mm plates. Each dish was then trans-
fected for 4 h in the presence of lipofectAMINE and Optimem
medium I (Life Technologies, Inc.) with 1 mg of pSV-b-galac-
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tosidase control vector (Promega Corp.) and 3 mg of one of
the following plasmids: pGL2basic, pGL2b-1, pGL2b-2,
pGL2b-4, or pGL2b-8. For the HIF-1a transient overexpres-
sion assays, 5 mg of the pCMVb-HA-HIF-1a vector were
cotransfected with an equal amount of one of the following
plasmids: pGL2basic, pGL2b-4, or pGL2b-8, together with 1
mg of pSV-b-Galactosidase control vector (quantities referred
per dish). All transfections were carried out in duplicate with
aliquots of transfection mixture from a single pool. After
transfection, cells were incubated in RPMI 1640 medium
supplemented with 10% FBS and were either treated with
DFX at 260 mM for 24 h or left under normoxic conditions for
the same time. Cells were then collected in EBC lysis buffer
with protease inhibitors (40 mM Tris, pH 8.0, 120 mM NaCl,
0.5% NP-40, 1 mM AEBSF, 10 mg/ml aprotinin, 1 mM NaVO4,
10 mg/ml leupeptin), and luciferase and b-galactosidase ac-
tivities were determined according to the manufacturer’s in-
structions using a TopCount NXT Packard luminometer and a
Bio-Rad Laboratories, Inc. 3550 Microplate Reader. Lucif-
erase readings were normalized by the b-galactosidase val-
ues to correct for differences in transfection efficiency and
extract preparation. For each construct transfectants, data
were expressed as fold increase of the luciferase value ob-
tained with the DFX treatment as compared with the lucif-
erase value obtained in normoxic conditions, which was ar-
bitrarily defined as 1. Data were statistically evaluated by a
two-tailed one-sample Student’s t test using Prism 3.0 soft-
ware. Differences were regarded as significant at a value of
P , 0.05.
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